ThromboGenics

08/09/2010

TIME: 15:14:14

LAST

17.64 €

OPEN

17.07 €

CHANGE

3.76 %


I Microplasmin I Anti-PlGF I Anti-factor VIII

Microplasmin I Eye disease I Thrombotic disease

Eye disease I TOP

Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.

de Smet, M. D., Gandorfer, A., Stalmans, P., Veckeneer, M., Feron, E., Pakola, S., and Kampik, A.

Ophthalmology. 2009 Jul; 116(7):1349-55, 1355.

Enzymatic vitreolysis.

Lopez-Lopez, F., Rodriguez-Blanco, M., Gomez-Ulla, F., and Marticorena, J.

Curr.Diabetes Rev. 2009 Feb; 5(1):57-62.

Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels.

Giblin, F. J., Quiram, P. A., Leverenz, V. R., Baker, R. M., Dang, L., and Trese, M. T.

Exp.Eye Res. 2009 Feb; 88(2):286-292.

Microplasmin: ex vivo characterization of its activity in porcine vitreous.

de Smet, M. D., Valmaggia, C., Zarranz-Ventura, J., and Willekens, B.

Invest Ophthalmol.Vis.Sci. 2009 Feb; 50(2):814-819.

Pharmacologic vitreodynamics and molecular flux.

Goldenberg, D. T. and Trese, M. T.

Dev.Ophthalmol. 2009; 44:31-6. 2009 Jun 3.31-36.

Microplasmin-assisted vitrectomy.

Gandorfer, A.

Dev.Ophthalmol. 2009; 44:26-30. 2009 Jun 3.26-30.

Enzymatic vitreous disruption.

Gandorfer, A.

Eye (Lond). 2008 Oct; 22(10):1273-1277.

Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels.

Stefansson, E.

Retina. 2008 Oct; 28(8):1175-1176.

Experimental evaluation of microplasmin - an alternative to vital dyes.

Gandorfer, A.

Dev.Ophthalmol. 2008; 42:153-9.153-159.

Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels.

Quiram, P. A., Leverenz, V. R., Baker, R. M., Dang, L., Giblin, F. J., and Trese, M. T.

Retina. 2007 Oct; 27(8):1090-1096.

Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients.

Sebag, J., Ansari, R. R., and Suh, K. I.

Graefes Arch.Clin.Exp.Ophthalmol. 2007 Apr; 245(4):576-580.

Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.

Sakuma, T., Tanaka, M., Mizota, A., Inoue, J., and Pakola, S.

Invest Ophthalmol.Vis.Sci. 2005 Sep; 46(9):3295-3299.

Molecular biology of pharmacologic vitreolysis.

Sebag, J.

Trans.Am.Ophthalmol.Soc. 2005; 103:473-94.473-494.

Posterior vitreous detachment induced by microplasmin.

Gandorfer, A., Rohleder, M., Sethi, C., Eckle, D., Welge-Lussen, U., Kampik, A., Luthert, P., and Charteris, D.

Invest Ophthalmol.Vis.Sci. 2004 Feb; 45(2):641-647.

Thrombotic disease I TOP

A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis.

Verhamme, P., Jerome, M., Goossens, G., Devis, J., Maleux, G., and Stas, M.

J.Thromb.Thrombolysis. 2009 Nov; 28(4):477-481.

Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.

Dommke, C., Turschner, O., Stassen, J. M., Van de Werf, F., Lijnen, H. R., and Verhamme, P.

J.Thromb.Thrombolysis. 2009 Oct; Epub ahead of print

Randomized, Placebo-Controlled, Dose-Ranging Clinical Trial of Intravenous Microplasmin in Patients With Acute Ischemic Stroke.

Thijs, V. N., Peeters, A., Vosko, M., Aichner, F., Schellinger, P. D., Schneider, D., Neumann-Haefelin, T., Rother, J., Davalos, A., Wahlgren, N., and Verhamme, P.

Stroke. 2009 Oct; Epub ahead of print

Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.
Pakola, S., Cahillane, G., Stassen, J. M., Lijnen, H. R., and Verhamme, P.
Clin.Ther. 2009 Aug; 31(8):1688-1706.

Effects of microplasmin on recovery in a rat embolic stroke model.

Rasmussen, R. S., Overgaard, K., Pakola, S., and Boysen, G.

Neurol.Res. 2008 Feb; 30(1):75-81.

Systemic reperfusion therapy in acute ischemic stroke.

Martinez-Sanchez, P., Diez-Tejedor, E., Fuentes, B., Ortega-Casarrubios, M. A., and Hacke, W.

Cerebrovasc.Dis. 2007; 24 Suppl 1:143-52.

Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.

Suzuki, Y., Chen, F., Ni, Y., Marchal, G., Collen, D., and Nagai, N.

Stroke. 2004 Oct; 35(10):2402-2406.

Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.

Suzuki, Y., Nagai, N., and Collen, D.

J.Thromb.Haemost. 2004 Sep; 2(9):1617-1621.

Recombinant human microplasmin: production and potential therapeutic properties.

Nagai, N., Demarsin, E., Van, Hoef B., Wouters, S., Cingolani, D., Laroche, Y., and Collen, D.

J.Thromb.Haemost. 2003 Feb; 1(2):307-313.

Last update: November 13, 2009

Inspired by Echo